Jonathan Naudé

Endogenous Markers of Two Separate Hypoxia Response Pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) Are Associated With Radiotherapy Failure in Head and Neck Cancer Patients Recruited in the CHART Randomized Trial

Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis

Head and neck squamous cell carcinoma

A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck

Diffusion weighted MR imaging in acute vertebral compression fractures: differentiation between malignant and benign causes

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

Head and neck cancer

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

Extracranial applications of diffusion-weighted magnetic resonance imaging

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data

Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology

Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology?

Hypoxia in cancer: significance and impact on clinical outcome

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial

Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial

Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial

Update on chemoradiotherapy for head and neck cancer

Radiotherapy for cancer of the head and neck: altered fractionation regimens

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

Drug Resistance and the Solid Tumor Microenvironment

Diffusion-Weighted MR Imaging for Differentiation of Benign Fracture Edema and Tumor Infiltration of the Vertebral Body

Head and Neck Cancer

ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context

Nanotechnology for Multimodal Synergistic Cancer Therapy

Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States

Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology

Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck

Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14

Vertebral Metastases: Assessment with Apparent Diffusion Coefficient

Mitomycin C (MMC) and Unconventional Fractionation (V-Chart) in Advanced Head and Neck Cancer

Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers